Liang Li

1990,.1995.2000.2001,,2003,2014.2011-2012 MD Anderson cancer center. “ ”,; 1; 1; 1. 22,SCI 16, 62. 7 CSCO CSCO 2006; 2008; 2009; 2009; 2010; 2014; 2018 (1) Wu D, Liang L, Nie L, Nie J, Dai L, Hu W, Zhang J, Chen X, Han J, Ma X, Tian G, Han S, Long J, Wang Y, Zhang Z, Xin T, Fang J. Efficacy, safety and predictive indicators of apatinib after multilines treatment in advanced nonsquamous nonsmall cell lung cancer: Apatinib treatment in nonsquamous NSCLC. Asia Pac J Clin Oncol. 2018 Mar 24, 1.959 (Q4) (2) Ma F, Liu WJ, Liang L, Tang B, Zhang CY. Sensitive detection of alkaline phosphatase by dephosphorylation-initiated transcription reaction-mediated dual signal amplification. Chem Commun (Camb). 2018;54(19):2413-2416 6.29(Q1) (3) Wang LJ, Ren M, Liang L, Zhang CY. Controllable fabrication of bio-bar codes for dendritically amplified sensing of human T-lymphotropic viruses. Chem Sci. 2018;9(22):4942-4949. 9.063(Q1) (4) Wang M, Liang L, Lei X, Multani A, Meric-Bernstam F, Tripathy D, Wu Y, Chen H, Zhang H.Evaluation of cMET aberration by immunohistochemistry and fluorescence in situ hybridization (FISH) in triple negative breast cancers. Ann Diagn Pathol. 2018;35:69-76. 1.633(Q4) (5) Li F, Zhu T, Yue Y, Zhu X, Wang J, Liang L. Preliminary mechanisms of regulating PD-L1 expression in non-small cell lung cancer during the EMT process. Oncol Rep 2018;40(2):775-782. 2.976(Q3) (6) Xu H, Zhang Q, Liang L*, Li J, Liu Z, Li W, Yang L, Yang G, Xu F, Ying J, Zhang S, Wang Y. Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants. Cancer Med. 2020;9(10):3328-3336. 4.6(Q3) (7) Gu Y, Xu Y, Zhuang H, Jiang W, Zhang H, Li X, Liu Y, Ma L, Zhao D, Cheng Y, Yu Y, Liu P, Qin J, Chen X, Gao J, Wang M, Liang L, Cao B. Value and significance of brain radiation therapy during first-line EGFR-TKI treatment in lung adenocarcinoma with EGFR sensitive mutation and synchronous brain metastasis: Appropriate timing and technique. Thorac Cancer. 2021;12(23):3157-3168. 3.223 (Q3) (8) Qian L, Zhaohui Z, Yaping X, Zhentian L, Zhentao L, Qiqi W, Yangchun G, Yan'e L, Wencheng Y, Fumei Y, Yanhong Y, Baoshan C, Li L. Blood T cell diversity associated with the prognosis of advanced non-small cell lung carcinoma treated with first-line pemetrexed based chemotherapy. Thorac Cancer. 2021;12(7):997-1005. 3.223 (Q3) (9) Li Q, Sun T, Zhang H, Liu W, Xiao Y, Sun H, Yin W, Yao Y, Gu Y, Liu Y, Yi F, Wang Q, Yu J, Cao B, Liang L. Characteristics and Clinical Implication of UGT1A1 Heterozygous Mutation in Tumor. Zhongguo Fei Ai Za Zhi. 2022;25(3):137-146. 1、,,,,,,,,,,,,,,,. 《 》., 2005 11;: 1. 2、, Waston,M.,. 《 》., 2006 3;: 1. 3、,,,;,; (ICRP) 94 《 》,, 2007 8;: 3,. 4、,,.,., 2007.:. 5、,.,,, 2014.. 6、,, 2014.. 7、.,.,2017.9